Plain English summary B owel cancer is the second most common cause of cancer death in the UK. When the cancer is confined to the bowel and/or surrounding lymph nodes (early bowel cancer), it can often be treated with an operation. Following surgery, many patients will be cured; however, for others, the cancer may come back (recur) either locally in the bowel or in another organ such as the liver. Consequently, after surgery for early bowel cancer, clinicians often follow up patients in the hope of detecting any recurrent cancer at an early and treatable stage. The way in which patients are followed up is variable. Some patients have regular computerised tomography (CT; detailed radiography) scans and/or blood tests to look for signs of cancer. Others are simply advised to report any concerning symptoms.
The FACS (Follow-up After Colorectal Surgery) trial was undertaken to determine the most effective form of follow-up. Patients were allocated to one of four follow-up regimens: (1) minimal follow-up with a single CT scan, (2) regular CT scans, (3) regular blood tests with a single CT scan or (4) both regular CT scans and blood tests. The results demonstrate that regular follow-up with either CT scans or blood tests is better than minimal follow-up at detecting recurrent cancer at a treatable stage. There was no benefit of having both CT scans and blood tests. Of the intensive follow-up strategies, regular blood tests with a single CT scan appears to be both economical and well accepted by patients.
HTA programme
The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.
The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.
For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta
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